Parameter
| Biomarker | NPTX2 | Full name | Neuronal Pentraxin 2 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognostic Assessment |
| Disease | Alzheimer's Disease | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | CSF (SIMOA, Immunoassay) | ||
| Pathobiological Mechanisms | A member of the neuronal pentraxin family that maintains synaptic stability; decreased expression in AD leads to synaptic vulnerability. | ||||
| Clinical Availability Status | Research application: CSF levels are decreased in AD patients, positively correlated with tau pathology progression. | ||||
| Notes and Dynamics | Can predict the risk of MCI conversion to AD; lower baseline levels indicate higher conversion risk. | ||||